| 000 | 01664 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250512032452.0 | ||
| 264 | 0 | _c19880922 | |
| 008 | 198809s 0 0 eng d | ||
| 022 | _a0149-5992 | ||
| 024 | 7 |
_a10.2337/diacare.11.4.337 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSamad, A H | |
| 245 | 0 | 0 |
_aEffects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo. _h[electronic resource] |
| 260 |
_bDiabetes care _cApr 1988 |
||
| 300 |
_a337-44 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_a1-Deoxynojirimycin _xanalogs & derivatives |
| 650 | 0 | 4 | _a3-Hydroxybutyric Acid |
| 650 | 0 | 4 |
_aAlanine _xblood |
| 650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 | _aEating |
| 650 | 0 | 4 |
_aFatty Acids, Nonesterified _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlucosamine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aGlycerol _xblood |
| 650 | 0 | 4 | _aGlycoside Hydrolase Inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxybutyrates _xblood |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aImino Pyranoses |
| 650 | 0 | 4 |
_aInsulin _xblood |
| 650 | 0 | 4 |
_aLactates _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyruvates _xblood |
| 700 | 1 | _aTy Willing, T S | |
| 700 | 1 | _aAlberti, K G | |
| 700 | 1 | _aTaylor, R | |
| 773 | 0 |
_tDiabetes care _gvol. 11 _gno. 4 _gp. 337-44 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2337/diacare.11.4.337 _zAvailable from publisher's website |
| 999 |
_c3048124 _d3048124 |
||